Physician profile
Cesar A Conde
NPI 1932159043
$4,087.64
in general payments reported to CMS, 2019-2025
13 companies · $44.38 in 2025
The $44.38 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $3,269 · 2021: $278 · 2022: $30.72 · 2023: $25.45 · 2024: $296 · 2025: $44.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,369.20 | 2020-2021 | |
| Atricure, INC. | $177.77 | 2021 | |
| Edwards Lifesciences Corporation | $175.43 | 2024 | |
| Medtronic Vascular, INC. | $101.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.25 | 2019-2024 | |
| Exact Sciences Corporation | $45.97 | 2024 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $25.45 | 2023 | Inpefa |
| Cleerly, INC. | $25.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Novo Nordisk INC | $24.14 | 2024 | Ozempic, Rybelsus |
| Heartflow, INC. | $19.38 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.78 | 2024 | Xarelto |
| Lilly USA, LLC | $17.58 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Conde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.